Core Viewpoint - The company is expected to meet market expectations for its 2025 performance, with projected revenue of 642 million yuan and a non-IFRS net profit of 342 million yuan, indicating a year-on-year growth of 15.0% and 5.7% respectively [1][2] Revenue Growth - The increase in revenue is driven by a rise in the number of products per client, with core precision marketing and enterprise solutions expected to generate 594 million yuan, reflecting a 16.0% year-on-year growth [1] - The number of pharmaceutical clients is projected to reach 269, an 18.0% increase year-on-year, with the total number of covered products rising to 653, a 29.1% increase [1] - The average number of products per enterprise is estimated to be 2.43, up from 2.22 in 2024, contributing to steady revenue growth [1] Profitability - The company anticipates a gross margin of 60.0%, a 1.4 percentage point increase year-on-year, attributed to improved revenue structure and scale effects [2] - The non-IFRS operating profit margin is projected to be 27.6%, reflecting a 4.5 percentage point increase year-on-year, indicating stable profitability in core operations [2] Cash and Dividends - As of the end of 2025, the company is expected to have cash and debt investments totaling approximately 4.5 billion yuan, with a dividend payout ratio of about 55% for the year, demonstrating a commitment to returning value to shareholders [2] Earnings Forecast and Valuation - The company maintains its non-IFRS operating profit forecasts at 197 million yuan and 231 million yuan for the upcoming periods [2] - The target price has been adjusted down by 16% to 11.4 HKD, based on a 15x target EV/EBIT valuation, with current trading at approximately 9x/8x for 2026/2027 EV/EBIT, indicating a potential upside of 34% [2]
医脉通(02192.HK)：业绩符合预期 利润端稳中有进